Vaccines for preventing herpes zoster (shingles) in older adults

May 5, 2016

Source: Cochrane 

Follow this link for abstract

Date of publication: March 2016

Publication Type: Cochrane Review

In a nutshell: Herpes zoster vaccine is effective in preventing herpes zoster disease and this protection can last three years. In general, zoster vaccine is well tolerated; it produces few systemic adverse events and injection site adverse events of mild to moderate intensity.

Enter B and W: two new meningococcal vaccine programmes launched

December 21, 2015

Source: Archives of Diseases in Childhood, 2016, 101 (1), pp. 91-95

Follow this link for abstract

Date of publication: October 2015

Publication Type: Review

In a nutshell: In 2015, the UK became the first country in the world to have a comprehensive routine meningococcal vaccine programme targeting all of the main capsular groups of N. meningitidis. 1 An infant vaccine programme against meningococcal capsular group B Neisseria meningitidis (MenB) was launched from 1st September with an aim to reduce endemic MenB disease in early childhood. On 1st August 2015, an adolescent programme against groups A, C, W and Y meningococci (MenACWY) was rolled out to halt a growing outbreak of capsular group W disease (MenW) caused by a hypervirulent clone of N. meningitidis, in addition to maintaining control against MenC disease provided by the current adolescent programme.

Length of publication: 5 page article

Face to face interventions for informing or educating parents about early childhood vaccination

June 25, 2013

Source: The Cochrane Library, 2013 May 31;5:CD010038. 

Follow this link for full-text

Date of publication: May 2013

Publication Type: Review

In a nutshell: Childhood vaccination (also described as immunisation) is an important and effective way to reduce childhood illness and death. However, there are many children who do not receive the recommended vaccines because their parents do not know why vaccination is important, do not understand how, where or when to get their children vaccinated, disagree with vaccination as a public health measure, or have concerns about vaccine safety.

Face to face information or education sessions with parents about vaccination is one strategy that may improve vaccination rates and parental knowledge or understanding of vaccination. This review found seven studies with a total of 2978 participants that looked at the effects of face to face vaccination information or education for parents in a mix of high- and low-income countries. The interventions were single- or multi-session educational sessions, delivered to individuals or to groups of parents or soon-to-be parents.

The studies suggest that face to face strategies do not consistently improve either immunisation rates or parent knowledge and understanding of vaccination, but the evidence was low to very low quality for these outcomes. Only one study measured the cost of a face to face case management strategy. In this study, the cost of fully immunising one additional child was eight times the cost of usual care, but the quality of this evidence was very low. No studies measured parents’ intention to vaccinate their child or parent experience of intervention, and none of the studies looked at possible harmful outcomes related to the intervention. The results of this review are limited by the small number of included studies, small number of outcomes measured and problems with the way the researchers decided who should receive the intervention and with the way outcomes were assessed.

Length of publication: 91 pages (Full Review)

Immunisation of adolescents in the UK

December 21, 2010

Source: Archives of Diseases in Childhood, 2010 Nov 30. [Epub ahead of print]

Follow this link for abstract

Date of publication: November 2010

Publication Type: Review

In a nutshell: The recent introduction of routine immunisation against human papillomavirus (HPV) in adolescent girls in the UK has focused attention on the potential for immunisation in this age group. In this review the authors suggest that this is an opportunity that is not being fully utilised. In particular, there are arguments for adolescent vaccines to boost immunity against Bordetella pertussis and Neisseria meningitidis infections, and the successful implementation of the HPV vaccine could be taken as a model to prevent another sexually transmitted carcinogenic infection, hepatitis B virus.

Length of publication: Unknown